Transcription factor pancreatic and duodenal homeobox-1 (PDX-1) plays an essential role in pancreatic development, β-cell differentiation, maintenance of normal β-cell function and tumorigenesis. PDX-1 expression is tightly controlled through a variety of mechanisms under different cellular contexts. We report here that overexpression of Notch1 intracellular domain (NICD), an activated form of Notch1, enhanced PDX-1 expression in both PDX-1 stable HEK293 cells and mouse insulinoma β-TC-6 cells, while NICD shRNA inhibited the enhancing effect. NICD-enhanced PDX-1 expression was accompanied by increased insulin expression/secretion and cell proliferation in β-TC-6 cells, which was reversed by NICD shRNA. Cre activation-induced specific expression of NICD in islet β cells of transgenic β NICD+/+ mice induced increased expression of PDX-1, insulin and proliferating cell nuclear antigen (PCNA) and decreased expression of p27 with accompanied fasting hyperinsulinemia and hypoglycemia and altered responses to intraperitoneal glucose tolerance test. Systemically delivered NICD shRNA suppressed islet expression of PDX-1 and reversed the hypoglycemia and hyperinsulinemia. Moreover, expression levels of NICD were correlated with those of PDX-1 in human pancreatic neuroendocrine tumor. Thus, Notch1 acts as a positive regulator for PDX-1 expression, cooperates with PDX-1 in the development of insulin overexpression and islet cell neoplasia and represents a potential therapeutic target for islet neoplasia.
References
[1]
Jonsson, J.; Carlsson, L.; Edlund, T.; Edlund, H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994, 371, 606–609, doi:10.1038/371606a0.
[2]
Stoffers, D.A.; Zinkin, N.T.; Stanojevic, V.; Clarke, W.L.; Habener, J.F. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat. Genet. 1997, 15, 106–110.
[3]
Ahlgren, U.; Jonsson, J.; Jonsson, L.; Simu, K.; Edlund, H. beta-cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the beta-cell phenotype and maturity onset diabetes. Genes Dev. 1998, 12, 1763–1768, doi:10.1101/gad.12.12.1763.
[4]
Brissova, M.; Shiota, M.; Nicholson, W.E.; Gannon, M.; Knobel, S.M.; Piston, D.W.; Wright, C.V.; Powers, A.C. Reduction in pancreatic transcription factor PDX-1 impairs glucose-stimulated insulin secretion. J. Biol. Chem. 2002, 277, 11225–11232, doi:10.1074/jbc.M111272200.
Al-Quobaili, F.; Montenarh, M. Pancreatic duodenal homeobox factor-1 and diabetes mellitus type 2 (review). Int. J. Mol. Med. 2008, 21, 399–404.
[7]
Ballian, N.; Liu, S.H.; Brunicardi, F.C. Transcription factor PDX-1 in human colorectal adenocarcinoma: A potential tumor marker? World J. Gastroenterol. 2008, 14, 5823–5826.
[8]
Jonmarker, S.; Glaessgen, A.; Culp, W.D.; Pisa, P.; Lewensohn, R.; Ekman, P.; Valdman, A.; Egevad, L. Expression of PDX-1 in prostate cancer, prostatic intraepithelial neoplasia and benign prostatic tissue. APMIS 2008, 116, 491–498, doi:10.1111/j.1600-0463.2008.01020.x.
[9]
Koizumi, M.; Doi, R.; Toyoda, E.; Masui, T.; Tulachan, S.S.; Kawaguchi, Y.; Fujimoto, K.; Gittes, G.K.; Imamura, M. Increased PDX-1 expression is associated with outcome in patients with pancreatic cancer. Surgery 2003, 134, 260–266, doi:10.1067/msy.2003.231.
[10]
Leys, C.M.N.S.; Rudzinski, E.; Kaminishi, M.; Montgomery, E.; Washington, M.K.; Goldenring, J.R. Expression of PDX-1 in human gastric metaplasia and gastric adenocarcinoma. Hum. Pathol. 2006, 37, 1162–1168, doi:10.1016/j.humpath.2006.04.011.
[11]
Liu, S.H.; Rao, D.D.; Nemunaitis, J.; Senzer, N.; Zhou, G.; Dawson, D.; Gingras, M.C.; Wang, Z.; Gibbs, R.; Norman, M.; et al. PDX-1 Is a Therapeutic Target for Pancreatic Cancer, Insulinoma and Islet Neoplasia Using a Novel RNA Interference Platform. PLoS One 2012, 7, e40452, doi:10.1371/journal.pone.0040452.
[12]
Sakai, H.E.Y.; Li, X.L.; Akiyama, Y.; Miyake, S.; Takizawa, T.; Konishi, N.; Tatematsu, M.; Koike, M.; Yuasa, Y. PDX-1 homeobox protein expression in pseudopyloric glands and gastric carcinomas. Gut 2004, 53, 323–330, doi:10.1136/gut.2003.026609.
[13]
Wang, X.P.; Li, Z.J.; Magnusson, J.; Brunicardi, F.C. Tissue MicroArray analyses of pancreatic duodenal homeobox-1 in human cancers. World J. Surg. 2005, 29, 334–338, doi:10.1007/s00268-004-7823-4.
[14]
Liu, T.; Gou, S.M.; Wang, C.Y.; Wu, H.S.; Xiong, J.X.; Zhou, F. Pancreas duodenal homeobox-1 expression and significance in pancreatic cancer. World J. Gastroenterol. 2007, 13, 2615–2618.
[15]
Liu, S.H.; Patel, S.; Gingras, M.C.; Nemunaitis, J.; Zhou, G.; Chen, C.; Li, M.; Fisher, W.; Gibbs, R.; Brunicardi, F.C. PDX-1: Demonstration of oncogenic properties in pancreatic cancer. Cancer 2011, 117, 723–733, doi:10.1002/cncr.25629.
[16]
Gidekel Friedlander, S.Y.; Chu, G.C.; Snyder, E.L.; Girnius, N.; Dibelius, G.; Crowley, D.; Vasile, E.; DePinho, R.A.; Jacks, T. Context-dependent transformation of adult pancreatic cells by oncogenic K-Ras. Cancer Cell 2009, 16, 379–389, doi:10.1016/j.ccr.2009.09.027.
[17]
Liu, S.; Ballian, N.; Belaguli, N.S.; Patel, S.; Li, M.; Templeton, N.S.; Gingras, M.C.; Gibbs, R.; Fisher, W.; Brunicardi, F.C. PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas 2008, 37, 210–220, doi:10.1097/MPA.0b013e31816a4a33.
[18]
Guo, D.; Ye, J.; Dai, J.; Li, L.; Chen, F.; Ma, D.; Ji, C. Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk. Res. 2009, 33, 678–685, doi:10.1016/j.leukres.2008.10.026.
[19]
Cohen, B.; Shimizu, M.; Izrailit, J.; Ng, N.F.; Buchman, Y.; Pan, J.G.; Dering, J.; Reedijk, M. Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer. Breast Cancer Res. Treat. 2010, 123, 113–124, doi:10.1007/s10549-009-0621-9.
[20]
Palomero, T.; Lim, W.K.; Odom, D.T.; Sulis, M.L.; Real, P.J.; Margolin, A.; Barnes, K.C.; O'Neil, J.; Neuberg, D.; Weng, A.P.; et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc. Natl. Acad. Sci. USA 2006, 103, 18261–18266, doi:10.1073/pnas.0606108103.
[21]
Jiao, X.; Wood, L.D.; Lindman, M.; Jones, S.; Buckhaults, P.; Polyak, K.; Sukumar, S.; Carter, H.; Kim, D.; Karchin, R.; et al. Somatic mutations in the Notch, NF-KB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes Chromosomes Cancer 2012, 51, 480–489, doi:10.1002/gcc.21935.
[22]
Lindsay, J.; Jiao, X.; Sakamaki, T.; Casimiro, M.C.; Shirley, L.A.; Tran, T.H.; Ju, X.; Liu, M.; Li, Z.; Wang, C.; et al. ErbB2 induces Notch1 activity and function in breast cancer cells. Clin. Transl. Sci. 2008, 1, 107–115, doi:10.1111/j.1752-8062.2008.00041.x.
[23]
Borggrefe, T.; Oswald, F. The Notch signaling pathway: Transcriptional regulation at Notch target genes. Cell. Mol. Life Sci. 2009, 66, 1631–1646, doi:10.1007/s00018-009-8668-7.
D'Souza, B.; Miyamoto, A.; Weinmaster, G. The many facets of Notch ligands. Oncogene 2008, 27, 5148–5167, doi:10.1038/onc.2008.229.
[26]
Radtke, F.; Raj, K. The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat. Rev. Cancer 2003, 3, 756–767, doi:10.1038/nrc1186.
[27]
Ranganathan, P.; Weaver, K.L.; Capobianco, A.J. Notch signalling in solid tumours: A little bit of everything but not all the time. Nat. Rev. Cancer 2011, 11, 338–351, doi:10.1038/nrc3035.
[28]
Pajvani, U.B.; Shawber, C.J.; Samuel, V.T.; Birkenfeld, A.L.; Shulman, G.I.; Kitajewski, J.; Accili, D. Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner. Nat. Med. 2011, 17, 961–967, doi:10.1038/nm.2378.
[29]
Fowler, J.C.; Zecchini, V.R.; Jones, P.H. Intestinal activation of Notch signaling induces rapid onset hepatic steatosis and insulin resistance. PLoS One 2011, 6, e20767, doi:10.1371/journal.pone.0020767.
[30]
Horn, S.; Kobberup, S.; Jorgensen, M.C.; Kalisz, M.; Klein, T.; Kageyama, R.; Gegg, M.; Lickert, H.; Lindner, J.; Magnuson, M.A.; et al. Mind bomb 1 is required for pancreatic beta-cell formation. Proc. Natl. Acad. Sci. USA 2012, 109, 7356–7361, doi:10.1073/pnas.1203605109.
[31]
Koo, B.K.; Lim, H.S.; Song, R.; Yoon, M.J.; Yoon, K.J.; Moon, J.S.; Kim, Y.W.; Kwon, M.C.; Yoo, K.W.; Kong, M.P.; et al. Mind bomb 1 is essential for generating functional Notch ligands to activate Notch. Development 2005, 132, 3459–3470, doi:10.1242/dev.01922.
[32]
Leal, M.C.; Surace, E.I.; Holgado, M.P.; Ferrari, C.C.; Tarelli, R.; Pitossi, F.; Wisniewski, T.; Castano, E.M.; Morelli, L. Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: Implications for cellular Abeta metabolism. Biochim. Biophys. Acta 2012, 1823, 227–235.
[33]
McKinnon, C.M.; Docherty, K. Pancreatic duodenal homeobox-1, PDX-1, a major regulator of beta cell identity and function. Diabetologia 2001, 44, 1203–1214, doi:10.1007/s001250100628.
[34]
Buteau, J.; Roduit, R.; Susini, S.; Prentki, M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells. Diabetologia 1999, 42, 856–864, doi:10.1007/s001250051238.
Arantes, V.C.; Reis, M.A.; Latorraca, M.Q.; Ferreira, F.; Stoppiglia, L.F.; Carneiro, E.M.; Boschero, A.C. Palmitic acid increase levels of pancreatic duodenal homeobox-1 and p38/stress-activated protein kinase in islets from rats maintained on a low protein diet. Br. J. Nutr. 2006, 96, 1006–1012, doi:10.1017/BJN20061950.
Lebrun, P.; Montminy, M.R.; van Obberghen, E. Regulation of the pancreatic duodenal homeobox-1 protein by DNA-dependent protein kinase. J. Biol. Chem. 2005, 280, 38203–38210, doi:10.1074/jbc.M504842200.
[39]
Boucher, M.J.; Selander, L.; Carlsson, L.; Edlund, H. Phosphorylation marks IPF1/PDX1 protein for degradation by glycogen synthase kinase 3-dependent mechanisms. J. Biol. Chem. 2006, 281, 6395–6403, doi:10.1074/jbc.M511597200.
[40]
Zhou, G.; Gingras, M.C.; Liu, S.H.; Li, D.; Li, Z.; Catania, R.L.; Stehling, K.M.; Li, M.; Paganelli, G.; Gibbs, R.A.; et al. The hypofunctional effect of P335L single nucleotide polymorphism on SSTR5 function. World J. Surg. 2011, 35, 1715–1724, doi:10.1007/s00268-010-0939-9.
[41]
Zhou, G.; Liu, S.H.; Shahi, K.M.; Wang, H.; Duan, X.; Lin, X.; Feng, X.H.; Li, M.; Fisher, W.E.; Demayo, F.J.; et al. Negative regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5. Mol. Endocrinol. 2012, 26, 1225–1234, doi:10.1210/me.2012-1095.
[42]
Fujitani, Y.; Fujitani, S.; Boyer, D.F.; Gannon, M.; Kawaguchi, Y.; Ray, M.; Shiota, M.; Stein, R.W.; Magnuson, M.A.; Wright, C.V. Targeted deletion of a cis-regulatory region reveals differential gene dosage requirements for Pdx1 in foregut organ differentiation and pancreas formation. Genes Dev. 2006, 20, 253–266, doi:10.1101/gad.1360106.
[43]
Wu, K.L.; Gannon, M.; Peshavaria, M.; Offield, M.F.; Henderson, E.; Ray, M.; Marks, A.; Gamer, L.W.; Wright, C.V.; Stein, R. Hepatocyte nuclear factor 3beta is involved in pancreatic beta-cell-specific transcription of the pdx-1 gene. Mol. Cell. Biol. 1997, 17, 6002–6013.
[44]
Gao, N.; LeLay, J.; Vatamaniuk, M.Z.; Rieck, S.; Friedman, J.R.; Kaestner, K.H. Dynamic regulation of Pdx1 enhancers by Foxa1 and Foxa2 is essential for pancreas development. Genes Dev. 2008, 22, 3435–3448, doi:10.1101/gad.1752608.
[45]
Humphrey, R.K.; Yu, S.M.; Flores, L.E.; Jhala, U.S. Glucose regulates steady-state levels of PDX1 via the reciprocal actions of GSK3 and AKT kinases. J. Biol. Chem. 2010, 285, 3406–3416, doi:10.1074/jbc.M109.006734.
[46]
Kishi, A.; Nakamura, T.; Nishio, Y.; Maegawa, H.; Kashiwagi, A. Sumoylation of Pdx1 is associated with its nuclear localization and insulin gene activation. Am. J. Physiol. Endocrinol. Metab. 2003, 284, E830–E840.
[47]
Kim, Y.C.; Kim, S.Y.; Mellado-Gil, J.M.; Yadav, H.; Neidermyer, W.; Kamaraju, A.K.; Rane, S.G. RB regulates pancreas development by stabilizing Pdx1. EMBO J. 2011, 30, 1563–1576, doi:10.1038/emboj.2011.57.
[48]
Rafiq, I.; da Silva Xavier, G.; Hooper, S.; Rutter, G.A. Glucose-stimulated preproinsulin gene expression and nuclear trans-location of pancreatic duodenum homeobox-1 require activation of phosphatidylinositol 3-kinase but not p38 MAPK/SAPK2. J. Biol. Chem. 2000, 275, 15977–15984.
[49]
Furukawa, N.; Shirotani, T.; Araki, E.; Kaneko, K.; Todaka, M.; Matsumoto, K.; Tsuruzoe, K.; Motoshima, H.; Yoshizato, K.; Kishikawa, H.; et al. Possible involvement of atypical protein kinase C (PKC) in glucose-sensitive expression of the human insulin gene: DNA-binding activity and transcriptional activity of pancreatic and duodenal homeobox gene-1 (PDX-1) are enhanced via calphostin C-sensitive but phorbol 12-myristate 13-acetate (PMA) and Go 6976-insensitive pathway. Endocr. J. 1999, 46, 43–58, doi:10.1507/endocrj.46.43.
[50]
Kawamori, D.; Kaneto, H.; Nakatani, Y.; Matsuoka, T.A.; Matsuhisa, M.; Hori, M.; Yamasaki, Y. The forkhead transcription factor Foxo1 bridges the JNK pathway and the transcription factor PDX-1 through its intracellular translocation. J. Biol. Chem. 2006, 281, 1091–1098.
Tang, Z.; Kadesch, T. Identification of a novel activation domain in the Notch-responsive transcription factor CSL. Nucleic Acids Res. 2001, 29, 2284–2291, doi:10.1093/nar/29.11.2284.
[54]
Feanny, M.A.; Fagan, S.P.; Ballian, N.; Liu, S.H.; Li, Z.; Wang, X.; Fisher, W.; Brunicardi, F.C.; Belaguli, N.S. PDX-1 expression is associated with islet proliferation in vitro and in vivo. J. Surg. Res. 2008, 144, 8–16, doi:10.1016/j.jss.2007.04.018.
[55]
Murtaugh, L.C.; Stanger, B.Z.; Kwan, K.M.; Melton, D.A. Notch signaling controls multiple steps of pancreatic differentiation. Proc. Natl. Acad. Sci. USA 2003, 100, 14920–14925.
[56]
Dohda, T.; Maljukova, A.; Liu, L.; Heyman, M.; Grander, D.; Brodin, D.; Sangfelt, O.; Lendahl, U. Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines. Exp. Cell Res. 2007, 313, 3141–3152, doi:10.1016/j.yexcr.2007.04.027.
[57]
Wang, H.; Chen, Y.; Fernandez-Del, C.; Yilmaz, O.; Deshpande, V. Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: A critical look at notch signaling pathway. Mod. Pathol. 2013, 26, 139–147, doi:10.1038/modpathol.2012.143.
[58]
Zhou, G.; Gingras, M.C.; Liu, S.H.; Sanchez, R.; Edwards, D.; Dawson, D.; Christensen, K.; Paganelli, G.; Gibbs, R.; Fisher, W.; et al. SSTR5 P335L monoclonal antibody differentiates pancreatic neuroendocrine neuroplasms with different SSTR5 genotypes. Surgery 2011, 150, 1136–1142, doi:10.1016/j.surg.2011.09.044.
